The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $358.
Royal Caribbean Group
RCL · a US exchange · USD · Market cap $90.9B · 107,950 employees
Royal Caribbean Cruises Ltd.
FAIL · Does not pass the screenPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price303.15 USD at the 19 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.52)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $338.01 to $563.36, base estimate $404.34 (screen dated 2026-11-19).
- Trend Markup
- Insiders insiders sold, $62,109,253, latest filing 2026-11-11
- Positioning political buying, disclosed 2026-10-13
- Options put/call open interest 0.52, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Royal Caribbean Group holds its Markup at $303.15. Consolidating, no directional conviction, held for 1 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $303.15 |
| Valuation | 20.11 trailing · 16.59 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.86 |
Five Screens: RCL's Results
FAIL. Debt ratio
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 52.94% | Below 33% | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Pass |
| Receivables | 2.74% | Below 49% | Pass |
| Revenue purity | 0.13% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Royal Caribbean's business is in a permissible area, but its interest-bearing debt is about 53% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when RCL's ethical verdict changes
Today RCL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 25% discount to our $404.34 fair value, strong competitive moat, 8.80% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 25.0% discount to the base estimate.
Third-party analyst targets: 27 covering, consensus Buy. The average target sits +18% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $404.34, with a range of $338.01 to $563.36, dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 16.6xpriced for continued growth |
| Trailing P/E | 20.1xa premium valuation |
| EPS, trailing | 16.90 |
| EPS, forward | 20.49 |
| Revenue growth | +8.8%steady growth |
| Profit margin | 23.8%healthy profit margins |
| Return on equity | 41.3%an exceptional return on shareholder capital |
| FCF yield | -0.06% |
| Dividend yield | 1.87% |
| Debt to equity | 1.94a meaningful debt load worth watching |
| Current ratio | 0.22below 1: short-term bills exceed liquid assets |
| Beta | 1.86much more volatile than the market |
| Short interest, float | 0.07% |
| 52-week range | 222.22 - 356.39 |
| Moat | STRONG |
| Market cap | $90.9B |
| Employees | 107,950 |
RCL-specific watchpoints · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (26 analysts) rates it buy, with a mean price target of $354.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (26 analysts) rates it strong buy, with a mean price target of $353.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 1%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (27 analysts) rates it buy, with a mean price target of $350. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Viking Is the Latest Cruise Line Stock to Survive the Market's Wild Waves Yahoo Finance · 16h ago
- Royal Caribbean (RCL) Recently Broke Out Above the 20-Day Moving Average Yahoo Finance · 20h ago
- What Will Move Carnival Stock Through Spring 2027? Yahoo Finance · 22h ago
- Can RCL's Resort Strategy Capture More of the $2T Vacation Market? Yahoo Finance · 2d ago
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off Yahoo Finance · 2d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-11 | Wilhelmsen Arne Alexander | Dir | S - Sale | 185,000 | $62,109,253 |
| 2026-11-06 | Wilhelmsen Arne Alexander | Dir | S - Sale | 476,674 | $159,824,006 |
| 2026-11-04 | Wilhelmsen Arne Alexander | Dir | S - Sale | 250,000 | $82,140,413 |
| 2026-10-30 | Montiel Maritza Gomez | Dir | S - Sale | 400 | $122,884 |
| 2026-10-28 | Lake Robert Alexander | SVP, CLO, Secretary | S - Sale | 1,000 | $298,430 |
| 2026-02-27 | WIERNICKI CHRISTOPHER J. | Director | 444 | · | |
| 2026-02-27 | WILHELMSEN ARNE ALEXANDER | Director | 771,607 | $243,570,580 | |
| 2026-02-24 | WILHELMSEN ARNE ALEXANDER | Director | 473,548 | $149,441,189 | |
| 2026-02-19 | WILHELMSEN ARNE ALEXANDER | Director | 206,442 | $65,426,312 | |
| 2026-02-17 | WILHELMSEN ARNE ALEXANDER | Director | 280,000 | $91,172,995 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-13 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-12 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-10-07 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $281.97 | +13.7% | · | $1,137 | +13.7% |
| 2 months | $245.81 | +30.5% | · | $1,305 | +30.5% |
| 3 months | $285.92 | +12.2% | $1.50 | $1,127 | +12.7% |
| 6 months | $253.27 | +26.6% | $3.00 | $1,278 | +27.8% |
| 1 year | $246.49 | +30.1% | $5.50 | $1,323 | +32.3% |
| 2 years | $224.57 | +42.8% | $8.55 | $1,466 | +46.6% |
| 3 years | $102.03 | +214.3% | $8.95 | $3,230 | +223.0% |
| 5 years | $77.79 | +312.2% | $8.95 | $4,237 | +323.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever RCL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.